An Introduction to Medicinal Chemistry

More documents

Recommendations

Info

Morphine 253 To conclude, the 6-hydroxyl group is not required for analgesic activity and its removal can be beneficial <strong>to</strong> analgesic activity. The double bond at 7-8 Several analogues including dihydromorphine (Fig. 12.6) have shown that
Page 1 and 2:
An Introduction to Medicinal Chemis
Page 3 and 4:
Preface This text is aimed at under
Page 5 and 6:
Contents Classification of drugs xi
Page 7 and 8:
Contents
Page 9 and 10:
Contents xi 11.16.2 Structure
Page 11 and 12:
Classification of drugs
Page 13 and 14:
1 • Drugs and the medicinal chemi
Page 15 and 16:
Whilst penicillin Drugs and the med
Page 17:
Drugs
Page 22 and 23:
10 The why and the wherefore Cytopl
Page 25:
Where do drugs work? 13 Amphoterici
Page 28:
16 Protein structure [ H O
Page 31 and 32:
The tertiary structure of proteins
Page 33 and 34:
The tertiary structure of proteins
Page 36 and 37:
24 Protein structure H-Bond Peptide
Page 38:
26 Protein structure again that ter
Page 43 and 44:
Substrate binding
Page 45 and 46:
Substrate binding at an active site
Page 47:
Substrate binding
Page 53 and 54:
R The catalytic role of enzymes Thy
Page 55 and 56:
I NH 2 CHO (OH Condensation R< The
Page 59 and 60:
Nerve Neurotransmitters
Page 61 and 62:
Receptors
Page 64 and 65:
52 Drug action at receptors Induced
Page 66 and 67:
54 Drug action at receptors MESSENG
Page 68:
56 Drug action at receptors RECEPTO
Page 72 and 73:
60 Drug action at receptors left-ha
Page 74 and 75:
62 Drug action
Page 76 and 77:
64 Drug action
Page 78 and 79:
66 Drug action at receptors D Neuro
Page 81 and 82:
Structure of DNA 69 NH 2 NHo NHo Ad
Page 83 and 84:
Structure
Page 85 and 86:
Drugs acting
Page 87:
Drugs acting on DNA 75 CH3—N: MEC
Page 90 and 91:
78 Nucleic acids end AMINO «A/* Ba
Page 93:
Summary 81
Page 96 and 97:
84 Drug development
Page 98 and 99:
86 Drug development | | Potential I
Page 100 and 101:
88 Drug development bonding or not,
Page 102 and 103:
90 Drug development 7.5.1 Variation
Page 104 and 105:
92 Drug development covered
Page 106 and 107:
94 Drug development avoiding patent
Page 108 and 109:
96 Drug development ,OH OH GLIPINE
Page 111:
Receptor theories
Page 115 and 116:
Lead compounds
Page 117 and 118:
A case study—oxamniquine
Page 119 and 120:
A case study—oxamniquine
Page 121 and 122:
A case study—oxamniquine 109 CH 3
Page 124 and 125:
112 Pharmacodynamics stream. Thirdl
Page 127 and 128:
Drug dose levels 115 can easily neg
Page 129 and 130:
Drug design for pharmacokinetic pro
Page 131 and 132:
Drug design
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139:
grown Neurotransmitters as drugs? 1
Page 142 and 143:
130 Quantitative structure-activity
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164:
Page 170 and 171:
158 Antibacterial agents
Page 173 and 174:
others. Antibacterial agents which
Page 175 and 176:
Antibacterial agents which act agai
Page 177 and 178:
Antibacterial agents which
Page 179 and 180:
Antibacterial agents which inhibit
Page 181 and 182:
Page 183:
is tolerated Antibacterial agents w
Page 186 and 187:
174 Antibacterial agents The proble
Page 188 and 189:
176 Antibacterial agents Permeabili
Page 190 and 191:
178 Antibacterial agents H0 2C—C
Page 192 and 193:
180 R
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Antibacterial agents which impair p
Page 213 and 214: Agents which
Page 215 and 216: Drug resistance 203 10.9 Drug resis
Page 217 and 218: 11- The peripheral nervous system
Page 219 and 220: Motor nerves
Page 221 and 222: Actions
Page 223 and 224: The cholinergic system 211 I j V Ac
Page 225: Agonists
Page 229: Agonists at the cholinergic recepto
Page 232 and 233: 220 The peripheral nervous system
Page 235 and 236: Antagonists
Page 237: Structural analogues based Antagoni
Page 240 and 241: 228 The peripheral nervous system I
Page 242 and 243: 230 The peripheral nervous system p
Page 244 and 245: 232 The peripheral nervous system ;
Page 247: Anticholinesterases
Page 250 and 251: 238 The peripheral nervous system r
Page 253 and 254: Anticholinesterase drugs
Page 255 and 256: Anticholinesterase drugs
Page 257: Pralidoxime—an organophosphate an
Page 260 and 261: 248 The opium analgesics Chinese de
Page 263: Morphine
Page 269 and 270: Development
Page 271 and 272: Development of morphine analogues 2
Page 277 and 278: Development of morphine analogues 2
Page 279: Development of morphine analogues 2
Page 282 and 283: 270 The opium analgesics analgesic
Page 284 and 285: 272 The opium analgesics acts as a
Page 287: Enkephalins
Page 290 and 291: 278 The opium analgesics narcotic a
Page 292: 280 The opium analgesics O II N —
Page 297: Searching
Page 301 and 302: Searching for a lead—AT-guanylhis
Page 303: Developing the lead—a chelation b
Page 307: Development of metiamide 295 meanin
Page 311: Development
Page 315 and 316:
Further studies—cimetidine analog
Page 317 and 318:
Page 319 and 320:
Page 321:
Famotidine and nizatidine 309 • R
Page 325 and 326:
Appendix
Page 327:
(vesicles) containing The action of
Page 331 and 332:
The action of nerves 319 x Briv "-
Page 333 and 334:
Secondary messengers
Page 335:
Secondary messengers 323 the proces
Page 338 and 339:
Appendix 4 • Bacteria and bacteri
Page 340 and 341:
Glossary ADDICTION Addiction can be
Page 342 and 343:
Further reading Albert,
Page 345 and 346:
drug addiction 1, 3, 5, 127, 248, 2
Page 347 and 348:
penillic acids 172 pentagastrin Ind
show all

An Introduction to Medicinal Chemistry

Create successful ePaper yourself

Delete template?

Save as template?